Search Within

Sergio Andres Giralt

Formats
  1. Meeting Abstract (642)
  2. Journal Article (376)
  3. Research Letter (20)
  4. Review (15)
  5. Guidelines (5)
  6. Correspondence (4)
  7. Editorial (4)
  8. Book Section (3)
Groups
  1. Bone Marrow Transplant (1069)
  2. Center for Hematologic Malignancies (1069)
  3. Department of Medicine (1069)
  4. Hematologic Malignancies, Division of (1069)
  5. Survivorship Research (703)
  6. CTCR Scholars (557)

More Groups

People
  1. Miguel-Angel Perales (429)
  2. Sean Devlin (380)
  3. Gunjan Shah (311)
  4. Michael Scordo (279)
  5. Heather Landau (263)
  6. Ann Jakubowski (242)

More People

Years
  1. 2025 (18)
  2. 2024 (65)
  3. 2023 (104)
  4. 2022 (77)
  5. 2021 (66)
  6. 2020 (91)

More Years

Publications
  1. Blood (314)
  2. Biology of Blood and Marrow Transplantation (275)
  3. Bone Marrow Transplantation (80)
  4. Clinical Lymphoma, Myeloma and Leukemia (60)
  5. Journal of Clinical Oncology (40)
  6. Transplantation and Cellular Therapy (36)

More Publications

Publishers
  1. Elsevier Inc. (386)
  2. American Society of Hematology (349)
  3. Nature Publishing Group (110)
  4. American Society of Clinical Oncology (42)
  5. Taylor & Francis Group (35)
  6. Ferrata Storti Foundation (13)

More Publishers

Results (1069)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Successful incorporation of electronic patient reported outcomes using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy
    Meeting Abstract

    Shah, G. L.; Lobaugh, S.; Sukhu, R.; Devlin, S. M.; Atkinson, T.; Kemeny, E.; Stetson, P.; Perales, M. A.; Giralt, S. A.; Scordo, M.
    Blood (2023)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3
    Meeting Abstract

    Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N. S.; Costa, L.; Vij, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • (131)I-apamistamab effectively achieved durable responses in patients with R/R AML irrespective of the presence of multiple high-risk factors
    Meeting Abstract

    Seropian, S.; Foran, J. M.; Gyurkocza, B.; Nath, R.; Choe, H.; Litzow, M. R.; Koshy, N.; Stiff, P. J.; Tomlinson, B. K.; Abhyankar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • (131)I-apamistamab-led allogeneic hematopoietic cell transplant significantly improves overall survival in patients with TP53 mutated R/R AML
    Meeting Abstract

    Choe, H.; Tomlinson, B. K.; Gyurkocza, B.; Nath, R.; Seropian, S.; Litzow, M. R.; Abboud, C. N.; Stiff, P. J.; Abhyankar, S.; Foran, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) who had received 2-4 prior regimens: Updated results from the phase 3 KarMMa-3 trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with triple-class-exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who received at least 3 lines of prior antimyeloma regimens in the KarMMa-3 phase 3 randomized controlled trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Rabbit antithymocyte (rATG) exposure and outcomes after hematopoietic cell transplantation: A real world experience from BMT CTN 1202
    Meeting Abstract

    Lakkaraja, M.; Mauguen, A.; Hosszu, K. K.; McAvoy, D.; Stewart, V.; Schmidt, G.; Levine, J.; Perales, M. A.; Giralt, S. A.; Baker, K. S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save